Health Canada vs FDA: Drug Approval Process Comparison

Health Canada vs FDA: Drug Approval Process Comparison

Key Takeaways

Organizational Structure Comparison

Health Canada and FDA operate under different governmental frameworks, which affects how drug review is organized and resourced.

Submission Type Mapping: NDS vs NDA

The two agencies use different terminology for equivalent submission types. Understanding the mapping is essential for planning parallel submissions.

Key Differences in Submission Type Logic

Biologics: In Canada, biosimilar biologic drugs are handled under Health Canada's biosimilar guidance rather than the small-molecule generic pathway. In the US, novel biologics file a BLA and biosimilars file a BLA under section 351(k) of the Public Health Service Act.

Generics: Both countries use abbreviated pathways (ANDS/ANDA) that rely on bioequivalence data rather than full clinical studies. However, the reference product definitions differ: Canada requires a Canadian Reference Product (CRP) with a valid DIN, while FDA requires a Reference Listed Drug (RLD) listed in the Orange Book.

Supplements: Both agencies require supplements for post-approval changes, but the classification of what constitutes a major vs. minor change follows different guidance. Health Canada uses a classification based on the MDSA guidance, while FDA uses the SUPAC framework and guidance-specific supplement categories.

Review Timeline Comparison

Review timelines are one of the most practical differences between the two agencies. Both agencies set performance targets, but the targets differ by submission type.

Standard Review Timelines

How Timelines Are Counted

A fundamental difference is how each agency handles deficiencies during review. Health Canada issues a Notice of Deficiency (NOD) that stops the review clock while the sponsor responds, then resumes the same review cycle. FDA issues a Complete Response Letter (CRL) that ends the review cycle entirely. The sponsor must then resubmit, starting a new PDUFA review clock.

This means Health Canada review timelines can extend significantly if multiple NODs are issued, while FDA timelines reset with each CRL/resubmission cycle.

Module 1 Differences

Both agencies require eCTD format with the standard ICH CTD structure (Modules 1-5). Modules 2-5 are harmonized across ICH regions. Module 1 is region-specific and differs substantially between Health Canada and FDA.

Module 1 Structure Comparison

Key Module 1 Differences

Application forms: Health Canada uses HC/SC 3011; FDA uses FDA Form 356h. Both capture similar information but with different formats and field requirements.

Labeling documents: This is the most significant content difference. Health Canada requires a Product Monograph (see labeling section below), while FDA requires a separate USPI, and potentially a Medication Guide, Patient Package Insert, or Instructions for Use.

Environmental assessment: FDA requires an Environmental Assessment (EA) or a claim for categorical exclusion under 21 CFR 25. Health Canada handles environmental assessment through the New Substances Notification Regulations under CEPA, separate from the drug submission.

Bilingual requirements: Health Canada requires bilingual (English/French) labeling for marketed products. FDA requires English only (though Spanish labeling may be voluntarily provided).

Risk management: FDA may require a Risk Evaluation and Mitigation Strategy (REMS) filed in Module 1. Health Canada requires a Risk Management Plan (RMP) but uses a different format modeled more closely on the EU-RMP.

Labeling Differences: Product Monograph vs USPI

The prescribing information documents differ significantly between the two countries.

Structural Comparison

Content Differences

The Product Monograph is a more comprehensive document than the USPI because it includes scientific information (pharmacology, toxicology) that FDA places in review documents rather than in labeling. This means the PM requires more effort to prepare but provides a single reference document for healthcare professionals.

Expedited Pathway Comparison

Both agencies offer mechanisms to accelerate review for drugs that address serious conditions. The pathways are conceptually similar but differ in eligibility criteria and mechanics.

Side-by-Side Comparison

Detailed Pathway Differences

Priority Review: Both agencies offer priority review. Health Canada reduces the review target from 300 to 180 days. FDA reduces the PDUFA goal from 10 to 6 months. The eligibility criteria are similar: the drug must treat a serious condition and offer a significant improvement over existing therapies.

NOC/c vs Accelerated Approval: Both pathways allow authorization based on promising evidence with required post-market commitments, but they operate under different legal and policy frameworks. Sponsors should evaluate each program against the current Health Canada NOC/c guidance and FDA accelerated approval authorities rather than assuming they are interchangeable.

Breakthrough Therapy (FDA only): FDA's Breakthrough Therapy Designation has no direct Health Canada equivalent. It provides intensive FDA guidance on development, organizational commitment, and rolling review eligibility. Health Canada's Priority Review provides faster review but not the intensive development-phase engagement that Breakthrough Therapy offers.

Fast Track (FDA only): FDA's Fast Track Designation facilitates development and review of drugs for serious conditions. It provides more frequent FDA meetings and rolling review eligibility. Health Canada does not have a formal equivalent, though pre-submission meetings and advance consideration partially address similar needs.

Drug Naming Conventions

Drug naming rules differ between the two countries and can affect labeling and marketing strategy.

The biologic naming difference is notable: FDA requires a unique four-letter suffix appended to the INN for all biologics (including reference products), while Health Canada uses the standard INN without a suffix.

Post-Market Requirements Comparison

Vanessa's Law (Canada)

In 2014, Canada enacted the Protecting Canadians from Unsafe Drugs Act (Vanessa's Law), which strengthened Health Canada's post-market authority. Key provisions include:

• Mandatory reporting of serious adverse drug reactions by healthcare institutions
• Authority to order label changes, require additional safety studies, or recall drugs
• Authority to compel drug manufacturers to revise safety information
• Increased fines for non-compliance

These provisions give Health Canada broader post-market enforcement authority compared to the pre-2014 framework.

Fee Structure Comparison

Cross-agency fee comparisons can be directionally useful, but they are not perfectly apples to apples because the fee categories, currencies, establishment frameworks, and statutory structures differ. For live planning, compare the current official schedules side by side for the exact submission and facility categories in scope.

Note: Fee amounts are approximate and subject to annual adjustment. Always verify current fees on the respective agency website before filing.

Collaboration and Mutual Recognition

Health Canada and FDA maintain collaborative relationships that affect regulatory strategy:

Project Orbis: Both agencies participate in Project Orbis, an FDA initiative for concurrent review of oncology products. Under Project Orbis, FDA shares its clinical review with participating agencies (including Health Canada), enabling more efficient simultaneous review.

Access Consortium: Health Canada participates in the Access Consortium (formerly known as the Australia-Canada-Singapore-Switzerland Consortium, or ACSS) work-sharing initiative with TGA (Australia), HSA (Singapore), Swissmedic (Switzerland), and MHRA (UK). The MHRA joined after Brexit, making it a five-member consortium. This is not an FDA initiative but demonstrates Health Canada's openness to collaborative review.

Mutual Recognition Agreements (MRAs): Canada and the US have an MRA covering GMP inspections, allowing each agency to rely on the other's inspection findings in certain circumstances.

FDA-HC Regulatory Cooperation: Regular information sharing on safety signals, inspection findings, and emerging regulatory issues. This cooperation has increased over the past decade and was accelerated during the COVID-19 pandemic.

Practical Implications for Dual Filing

For sponsors planning simultaneous submissions to both Health Canada and FDA:

Module 2-5 Efficiency

Modules 2-5 can be largely identical between the two submissions since both agencies follow the ICH CTD structure. The primary areas where Module 2-5 content may need Canadian-specific adjustments are:

• Clinical Overview (Module 2.5): Address relevance to Canadian patient population
• Quality Overall Summary (Module 2.3): Reference any Canadian manufacturing sites or DMFs

Module 1 Requires Separate Preparation

Module 1 must be prepared separately for each agency. The Product Monograph, application forms, labeling, and administrative documents are completely different between the two submissions.

Timeline Planning

Given the different review timelines and mechanisms (clock-stop vs. review cycle), sponsors should plan for the possibility that approvals may not be simultaneous. Filing in both jurisdictions at approximately the same time does not guarantee simultaneous approval.

Regulatory Strategy Considerations

• Consider whether Priority Review eligibility criteria are met in both jurisdictions
• Plan Product Monograph and USPI development in parallel, recognizing the different formats
• Ensure manufacturing sites hold both a DEL (for Canada) and appropriate FDA registration
• Plan for different post-market reporting requirements and timelines

Key Regulatory References

• Food and Drugs Act (R.S.C., 1985, c. F-27) (Canada)
• Food and Drug Regulations (C.R.C., c. 870) (Canada)
• Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) (US)
• 21 CFR Parts 312 and 314 (US)
• Health Canada Guidance on Management of Drug Submissions and Applications
• Health Canada Priority Review guidance
• Health Canada Product Monograph guidance
• FDA PDUFA fee and review framework materials
• FDA Expedited Programs guidance
• ICH M4 (Organization of the CTD)

References

This comparison was checked against agency materials available on March 18, 2026. Verify current requirements on each agency's official website before filing.